Resources

Access expert content and insights, including whitepapers, case studies, presentations, and other valuable resources here.

Cell and Virus Banking: 5 Considerations for Planning You…

Rapidly emerging as an important therapeutic tool for the treatment of cancer, oncolytic viruses (OVs) can be specifically engineered for tumo…

Virus Rescue and Cloning: Beginning the Virus Manufactur…

Oncolytic viruses (OVs) are a versatile class of therapeutic agents offering the ability to selectively target cancerous cells and mediate ant…

Cell Line Considerations for Manufacturing Oncolytic Viruses

With growing interest to develop treatments that circumvent the drawbacks of traditional first-line treatments for advanced cancers including …

GMP Manufacturing of Oncolytic Viruses: Critical Steps an…

The oncolytic virus (OV) sector needs to overcome several challenges to bring transformative cancer therapeutics to the clinic.   Not only …

What is the Secret to Oncolytic Virus Development?

There are few contract development and manufacturing organizations (CDMOs) capable of working with biopharmaceutical companies to develop adva…

Virus Particle Analysis by MADLS Technology

Over the past two decades, we have seen continued advancement of virus characterization and quantification technologies come to market due to …

Load more

Process Development

Full development services are offered to transfer and mature processes for optimized scale, productivity, product profile and cost of goods.

Analytical Development

Method development and transfer services span characterization and quality control assays for identity, purity, potency, titer, and safety.

QC Release & Stability Testing

In-house quality control and stability services ensure timely testing of bulk, in-process control, and final drug product.

Oncolytic Virus

Specialist in the manufacture of replication competent engineered and wild-type oncolytic viruses, with a deep track record you can trust.

Gene Therapy

Expertise across gene therapy vectors produced by transient, helper-virus, and stable producer cell lines minimize time-to-market.

Vaccines

Scalable capacity and effective cost of goods management for vaccine product development and manufacture.